Treatment-resistant depression complicates care, defying standard treatments, but new therapies are on the horizon, offering hope for more effective treatment options.
Untreated mental health issues, like Treatment-Resistant Depression (TRD), cost U.S. businesses billions annually in lost ...
Phase 2b clinical trial of GH001 in patients with treatment-resistant depression on track for completion of last patient visit in the open-label extension in Q1 2025Phase 1 clinical trial to evaluate ...
Learn about five serious mental health conditions that often necessitate inpatient treatment. Understanding these challenges ...
Compass Pathways gains Stifel's Buy rating as its COMP360 psilocybin treatment advances in Phase 3 trials. Key depression study data expected in 2025-2026.
Phase 2b clinical trial of GH001 in patients with treatment-resistant depression on track for completion of last patient visit in the open-label extension in Q1 2025Phase 1 clinical trial to evaluate ...
Avesta Ketamine and Wellness (Avesta), the leading provider of monitored ketamine care in the Washington, D.C., Maryland and ...
Highlights: Phase 3 COMP005 trial in participants with treatment resistant depression (TRD) 6-week top-line data on track for second quarter 2025 Phase 3 COMP006 in TRD is on track for ...
Canaccord analyst Sumant Kulkarni lowered the firm’s price target on Compass Pathways (CMPS) to $15 from $23 and keeps a Buy rating on the ...
St John of God Hospital in Dublin has said it is the first hospital in Ireland to introduce a special treatment for patients ...
We are excited that the first data readout from our pivotal phase 3 COMP360 program in treatment resistant depression continues on track with ...
A new non-invasive treatment for depression, which has been shown to deliver remission for one third of its patients, is to ...